Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study

Alessandro Introna, Eustachio D’Errico, Boris Modugno, Antonio Scarafino, Angela Fraddosio, Eugenio Distaso, Irene Tempesta, Antonella Mastronardi, Isabella Laura Simone Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari “Ald...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Introna A, D'Errico E, Modugno B, Scarafino A, Fraddosio A, Distaso E, Tempesta I, Mastronardi A, Simone IL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5737f980cef34534aa981a6ece45fa22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5737f980cef34534aa981a6ece45fa22
record_format	dspace
spelling	oai:doaj.org-article:5737f980cef34534aa981a6ece45fa222021-12-02T02:15:21ZAdherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study1178-2021https://doaj.org/article/5737f980cef34534aa981a6ece45fa222018-01-01T00:00:00Zhttps://www.dovepress.com/adherence-to-riluzole-in-patients-with-amyotrophic-lateral-sclerosis-a-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Alessandro Introna, Eustachio D’Errico, Boris Modugno, Antonio Scarafino, Angela Fraddosio, Eugenio Distaso, Irene Tempesta, Antonella Mastronardi, Isabella Laura Simone Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari “Aldo Moro,” Bari, Italy Objective: Riluzole is the first drug approved to treat amyotrophic lateral sclerosis (ALS). Recently, an oral suspension (OS) of riluzole was made available. Thus, the aim of our study was to evaluate the adherence to 2 formulations of riluzole in patients with ALS.Patients and methods: We enrolled 45 consecutive patients with ALS. At disease diagnosis, riluzole was prescribed in 2 different formulations depending on the severity of dysphagia (27/45 patients received tablets and 18/45 patients received OS). Side effects (SEs) and treatment adherence were investigated using a clinical questionnaire including the ©Morisky 8-item Medication Adherence Questionnaire.Results: Gastroenteric complaints were the most frequent SEs (58% in the tablet group and 48% in the OS group), followed by those at the nervous system (29% and 40%, respectively). No serious SEs related to treatment were reported. The rate of adherence to riluzole was independent of the formulation of the drug and consistent with other medications assumed for comorbidities (p=0.004). In the tablet group, low adherence was caused by SEs in 55.6% and by dysphagia in 44.4% of patients. In the OS group, SEs caused low adherence in 75% of patients. Independently of the drug formulation, patients with high or medium adherence to riluzole had a higher progression rate (p=0.002 and p=0.009, respectively) and a shorter time to generalization (TTG; p=0.01), compared to those with low adherence.Conclusion: Gastroenteric symptoms were the most frequent SE related to tablet as well as OS. The rate of adherence was independent of the formulation of riluzole and the number of medications assumed for comorbidities, and it was consistent with the severity of the disease. The low adherence was caused by dysphagia and SEs in the tablet group, whereas it was caused prevalently by SEs in the OS group. Keywords: adherence, riluzole, oral suspension, tablet, side effectsIntrona AD'Errico EModugno BScarafino AFraddosio ADistaso ETempesta IMastronardi ASimone ILDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 193-203 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Introna A D'Errico E Modugno B Scarafino A Fraddosio A Distaso E Tempesta I Mastronardi A Simone IL Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
description	Alessandro Introna, Eustachio D’Errico, Boris Modugno, Antonio Scarafino, Angela Fraddosio, Eugenio Distaso, Irene Tempesta, Antonella Mastronardi, Isabella Laura Simone Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari “Aldo Moro,” Bari, Italy Objective: Riluzole is the first drug approved to treat amyotrophic lateral sclerosis (ALS). Recently, an oral suspension (OS) of riluzole was made available. Thus, the aim of our study was to evaluate the adherence to 2 formulations of riluzole in patients with ALS.Patients and methods: We enrolled 45 consecutive patients with ALS. At disease diagnosis, riluzole was prescribed in 2 different formulations depending on the severity of dysphagia (27/45 patients received tablets and 18/45 patients received OS). Side effects (SEs) and treatment adherence were investigated using a clinical questionnaire including the ©Morisky 8-item Medication Adherence Questionnaire.Results: Gastroenteric complaints were the most frequent SEs (58% in the tablet group and 48% in the OS group), followed by those at the nervous system (29% and 40%, respectively). No serious SEs related to treatment were reported. The rate of adherence to riluzole was independent of the formulation of the drug and consistent with other medications assumed for comorbidities (p=0.004). In the tablet group, low adherence was caused by SEs in 55.6% and by dysphagia in 44.4% of patients. In the OS group, SEs caused low adherence in 75% of patients. Independently of the drug formulation, patients with high or medium adherence to riluzole had a higher progression rate (p=0.002 and p=0.009, respectively) and a shorter time to generalization (TTG; p=0.01), compared to those with low adherence.Conclusion: Gastroenteric symptoms were the most frequent SE related to tablet as well as OS. The rate of adherence was independent of the formulation of riluzole and the number of medications assumed for comorbidities, and it was consistent with the severity of the disease. The low adherence was caused by dysphagia and SEs in the tablet group, whereas it was caused prevalently by SEs in the OS group. Keywords: adherence, riluzole, oral suspension, tablet, side effects
format	article
author	Introna A D'Errico E Modugno B Scarafino A Fraddosio A Distaso E Tempesta I Mastronardi A Simone IL
author_facet	Introna A D'Errico E Modugno B Scarafino A Fraddosio A Distaso E Tempesta I Mastronardi A Simone IL
author_sort	Introna A
title	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
title_short	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
title_full	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
title_fullStr	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
title_full_unstemmed	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
title_sort	adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/5737f980cef34534aa981a6ece45fa22
work_keys_str_mv	AT intronaa adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT derricoe adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT modugnob adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT scarafinoa adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT fraddosioa adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT distasoe adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT tempestai adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT mastronardia adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy AT simoneil adherencetoriluzoleinpatientswithamyotrophiclateralsclerosisanobservationalstudy
_version_	1718402595630874624

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study

Ejemplares similares